You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三生國健(688336.SH):SSGJ-627注射液獲得藥物臨牀試驗批準通知書
格隆匯 04-03 17:17

格隆匯4月3日丨三生國健(688336.SH)公佈,公司SSGJ-627注射液收到國家藥品監督管理局覈準簽發的《藥物臨牀試驗批準通知書》,同意公司開展SSGJ-627注射液潰瘍性結腸炎(UC)的I期臨牀試驗。SSGJ-627注射液是三生國健創新研發,擁有自主知識產權的重組抗TL1A人源化單克隆抗體。TL1A(TNF配體相關分子1A)是腫瘤壞死因子超家族的成員,主要由內皮細胞表達。它與DR3(死亡受體3)結合,爲下遊信號通路提供刺激信號,調節效應細胞的增殖、活化、凋亡和細胞因子、趨化因子的產生。作爲粘膜免疫反應、過敏和自身免疫的中樞調節因子,TL1A/DR3在自身免疫和自身炎症性疾病中發揮關鍵作用,抑制TL1A在治療自身免疫和炎症性疾病中亦是一種有效策略。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account